Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Kevin S, Clive"'
Autor:
Kevin S. Clive, Sathibalan Ponniah, George E. Peoples, Ritesh Patil, Timothy J. Vreeland, Alan K. Sears, EA Mittendorf, Guy T. Clifton, Diane F. Hale, JP Holmes
Publikováno v:
Cancer Research. 71:P1-13
Background: We are conducting phase I/II clinical trials vaccinating breast cancer patients with E75, an HLA-A2/A3 restricted HER2/neu (HER2) peptide mixed with GM-CSF. The vaccine has been studied in the adjuvant setting to prevent recurrences in cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2aaa54ad0c6e3d2ac67e227abbf7ad5c
https://doi.org/10.1158/0008-5472.sabcs11-p1-13-02
https://doi.org/10.1158/0008-5472.sabcs11-p1-13-02
Autor:
George E. Peoples, Constantin N. Baxevanis, Jarrod P. Holmes, Guy T. Clifton, Nathan M. Shumway, Alan K. Sears, M. G. Carmichael, Michael Papamichail, Sathibalan Ponniah, Linda C. Benavides, Jeremy D. Gates, Kevin S. Clive, Sonia A. Perez, Elizabeth A. Mittendorf, David C. Van Echo
Publikováno v:
Expert Opinion on Biological Therapy. 11:1543-1550
Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8+ T-cell-el
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566ce1e29c923a240637835e8b30a9f3
https://doi.org/10.1517/14712598.2011.616889
https://doi.org/10.1517/14712598.2011.616889
Autor:
Matthew F Barchie, Joseph B. Sutcliffe, Lisa M Bell, Kevin S. Clive, Kevin P. Banks, Aaron D. Kirkpatrick, George E. Peoples, Joshua A. Tyler, Jeff S Saenger, Slava Belenkiy
Publikováno v:
Journal of Surgical Oncology. 104:741-745
BACKGROUND AND OBJECTIVES Routine pretreatment breast magnetic resonance imaging in newly diagnosed cancer patients remains controversial. We assess MRI accuracy and influence on mastectomy decisions after institution of standardized pretreatment MRI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b61a912fb95d96d07cd8d9cad4ffb956
https://doi.org/10.1002/jso.21960
https://doi.org/10.1002/jso.21960
Autor:
Alexander Stojadinovic, George E. Peoples, David G. McLeod, Lindsey Enewold, Kangmin Zhu, Jing Zhou, Kevin S. Clive, Scott R. Steele, John F. Potter
Publikováno v:
Journal of the National Medical Association. 103:343-350
Hispanic men have lower colorectal, prostate, and skin cancer screening rates than white non-Hispanic men. Programs designed to increase screening rates, including the national Screen for Life campaign specifically for promoting colorectal cancer (CR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa73eff6f89d2b5ad69cbb37d2ef1933
https://doi.org/10.1016/s0027-9684(15)30315-1
https://doi.org/10.1016/s0027-9684(15)30315-1
Autor:
Guy T. Clifton, Jarrod P. Holmes, Jeremy D. Gates, Sathibalan Ponniah, George E. Peoples, Alan K. Sears, Elizabeth A. Mittendorf, Linda C. Benavides, Mark G. Carmichael, Kevin S. Clive
Publikováno v:
Expert Review of Vaccines. 10:201-210
We have performed multiple adjuvant clinical trials using immunogenic peptides from the HER2/neu protein (AE37/E75/GP2) plus (GM-CSF) given intradermally to breast cancer patients. Four trials were performed with similar dose-escalation design with i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0e5d4a8554eedfbb0fca8c18e417ea1
https://doi.org/10.1586/erv.10.167
https://doi.org/10.1586/erv.10.167
Autor:
Timothy J. Vreeland, Kevin S. Clive, Ge. Peoples, Sathibalan Ponniah, JP Holmes, Ritesh Patil, Guy T. Clifton, Alan K. Sears, EA Mittendorf
Publikováno v:
Cancer Research. 70:P2-20
Background: We are conducting clinical trials of the HER2/neu E75-peptide+GM-CSF vaccine in clinically disease-free breast cancer patients at high risk for recurrence. Our Phase I/II trials have shown that the vaccine is safe and effective in stimula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2464ff8c3baf3c61befe53e4d3724376
https://doi.org/10.1158/0008-5472.sabcs10-p2-20-01
https://doi.org/10.1158/0008-5472.sabcs10-p2-20-01
Autor:
Elizabeth A. Mittendorf, G. Travis Clifton, Kevin S. Clive, Jarrod P. Holmes, George E. Peoples, Sathibalan Ponniah, Josh Tyler
Publikováno v:
Expert Review of Vaccines. 9:519-525
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vacci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e45f2a656698ee5d45a50799c329cc8
https://doi.org/10.1586/erv.10.40
https://doi.org/10.1586/erv.10.40
Autor:
George E. Peoples, Elizabeth A. Mittendorf, Josh Tyler, Sathibalan Ponniah, Jarrod P. Holmes, G. Travis Clifton, Kevin S. Clive
Publikováno v:
Journal of surgical oncology. 105(5)
Preclinical studies suggest that GP2, a HER2/neu-derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2-based vaccines are safe and effective in stimulating peptide-specific immunity. A GP2 peptide vaccine is curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b7b20c079cb08175cb3e9a3e0c63f9c
https://pubmed.ncbi.nlm.nih.gov/22441896
https://pubmed.ncbi.nlm.nih.gov/22441896
Autor:
Sathibalan Ponniah, Kevin S. Clive, Alexander Stojadinovic, Jeremy D. Gates, Ritesh Patil, George E. Peoples, Elizabeth A. Mittendorf, Linda C. Benavides, Jarrod P. Holmes, Alan K. Sears, Guy T. Clifton
The authors conducted exploratory phase 1-2 clinical trials vaccinating breast cancer patients with E75, a human leukocyte antigen (HLA) A2/A3-restricted HER-2/neu (HER2) peptide, and granulocyte-macrophage colony-stimulating factor. The vaccine is g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59f392478ecf91f6e5a3ee8a071d8075
https://europepmc.org/articles/PMC3428069/
https://europepmc.org/articles/PMC3428069/
Autor:
C. G. Ioannides, Sathibalan Ponniah, Guy T. Clifton, George E. Peoples, Alan K. Sears, Elizabeth A. Mittendorf, Jarrod P. Holmes, Kevin S. Clive
Publikováno v:
Human vaccines. 7(2)
Folate receptor alpha (FR α) is a membrane-bound transport protein with several features which make it an attractive target for cancer immunotherapy. FR α is largely shielded from the immune system in normal tissue but exposed while expressed on a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02784c9e6cc81f170dd6537138a0bd90
https://pubmed.ncbi.nlm.nih.gov/21321484
https://pubmed.ncbi.nlm.nih.gov/21321484